市场调查报告书
商品编码
1404039
生物标记发现外包服务市场-按类型(预测、预后、安全性、替代终点)、服务(基因组学、蛋白质组学、生物资讯学)、治疗领域(肿瘤学、心臟病学、心血管)、最终用途全球预测2024-2032Biomarker Discovery Outsourcing Services Market-By Type (Predictive, Prognostic, Safety, Surrogate Endpoints), Service (Genomics, Proteomics, Bioinformatics), Therapeutic Area (Oncology, Cardiology, Cardiovascular), End-use Global Forecast 2024-2032 |
在产业领导者增加投资和扩张的推动下,全球生物标记发现外包服务市场在 2024 年至 2032 年间的CAGR将达到 12.7%。随着知名公司扩大研发计划,对外包生物标记发现服务的需求也随之增加。
例如,2022 年 10 月,赛默飞世尔的临床研究部门 PPD 拨款 5,900 万美元,用于增强肯塔基州疫苗、细胞和基因治疗的样本管理和测试能力。此举符合 Thermo Fisher 的全球策略,旨在为临床研究提供全面的实验室和生物标记服务。 PPD 位于肯塔基州高地的现有 71,600 平方英尺设施目前提供中央实验室服务和生物标记业务,并为生物製药客户提供支援。
该市场迎合不同领域,包括製药和诊断,提供识别疾病和治疗的关键生物标记的专业知识。对个人化医疗和精准诊断的日益关注推动了这一需求,促使公司外包这些服务以获取创新见解,从而推动市场的成长和演变。
生物标誌物发现外包服务市场的总体份额根据类型、最终用途和地区进行分类。
预测性生物标记领域将在 2024 年至 2032 年间经历重大发展。这些标记物在预测疾病进展、治疗反应和患者结果方面发挥关键作用。随着精准医学的发展势头,製药和生物技术产业加强寻找预测性生物标记。专门从事生物标记发现的外包服务变得至关重要,有助于识别和验证这些预测指标。市场的成长与对个人化治疗的追求相一致,强调了预测生物标记在彻底改变患者护理和治疗效果方面的重要性。
从 2024 年到 2032 年,製药公司领域的生物标记发现外包服务市场规模将出现显着的复合CAGR。随着药物开发转向精准医疗,对可靠生物标记的需求不断加剧。对于旨在有效识别、验证和利用生物标记的製药公司来说,外包这些服务变得至关重要。该市场满足多样化的需求,提供生物标记发现的专业知识,并协助药物开发、临床试验和个人化医疗。对生物标誌物的高度依赖推动了市场的成长,展示了其在推进药物研究和治疗创新方面的关键作用。
欧洲生物标记发现外包服务产业将在 2024 年至 2032 年呈现出值得称讚的CAGR。该地区的製药和生物技术行业越来越依赖外包专业知识来识别和验证对客製化疗法至关重要的生物标誌物。欧洲产业专注于推动个人化医疗和加速药物开发,寻求生物标记发现的专业外包服务。
这种需求反映了欧洲对创新医疗保健解决方案的承诺,并强调了市场在塑造欧洲大陆医学研究和治疗的未来方面的关键作用。例如,2023 年 10 月,Almac 集团宣布斥资 8,000 万英镑,在其位于北爱尔兰克雷加文的全球基地建造大型製造、生产和诊断实验室设施。 Almac Diagnostic Services 为全球生物製药合作伙伴提供多样化的生物标记发现、开发和商业化解决方案。
Global Biomarker Discovery Outsourcing Services Market will witness 12.7% CAGR between 2024 and 2032, buoyed by increased investments and expansions by industry leaders. As prominent companies expand their research and development initiatives, the need for outsourced biomarker discovery services amplifies.
For instance, in October 2022, Thermo Fisher's clinical research arm, PPD, allocated $59 million toward enhancing sample management and testing capabilities for vaccines, cell, and gene therapy in Kentucky. This move aligned with Thermo Fisher's global strategy, aiming to furnish comprehensive lab and biomarker services for clinical research. PPD's existing 71,600 square-foot facility in Highland Heights, Kentucky currently houses central lab services and biomarker operations and supports biopharmaceutical clients.
This market caters to diverse sectors, including pharmaceuticals and diagnostics, offering expertise in identifying crucial biomarkers for diseases and treatments. The rising focus on personalized medicine and precision diagnostics fuels this demand, prompting companies to outsource these services for innovative insights, driving the market's growth and evolution.
The overall Biomarker Discovery Outsourcing Services Market share is classified based on the type, end-use, and region.
Predictive biomarkers segment will undergo significant development from 2024 to 2032. These markers play a pivotal role in forecasting disease progression, treatment response, and patient outcomes. As precision medicine gains momentum, pharmaceutical and biotech sectors intensify efforts to identify predictive biomarkers. Outsourcing services specialized in biomarker discovery become crucial, aiding in the identification and validation of these predictive indicators. The market's growth aligns with the quest for personalized therapeutics, emphasizing the significance of predictive biomarkers in revolutionizing patient care and treatment efficacy.
Biomarker discovery outsourcing services market size from the pharmaceutical companies segment will register a noteworthy CAGR from 2024 to 2032. As drug development pivots towards precision medicine, the quest for reliable biomarkers intensifies. Outsourcing these services becomes pivotal for pharmaceutical firms aiming to identify, validate, and utilize biomarkers efficiently. This market caters to diverse needs, offering expertise in biomarker discovery and aiding in drug development, clinical trials, and personalized medicine. The heightened reliance on biomarkers fuels the market's growth, showcasing its pivotal role in advancing pharmaceutical research and therapeutic innovations.
Europe biomarker discovery outsourcing services industry will showcase a commendable CAGR from 2024 to 2032. The region's pharmaceutical and biotech sectors increasingly rely on outsourced expertise to identify and validate biomarkers crucial for tailored therapies. With a focus on advancing personalized medicine and accelerating drug development, European industries seek specialized outsourcing services in biomarker discovery.
This demand reflects Europe's commitment to innovative healthcare solutions and underscores the market's pivotal role in shaping the future of medical research and therapeutics on the continent. For instance, in October 2023, Almac Group announced an £80 million initiative to construct expansive manufacturing, production, and diagnostic laboratory facilities at its global base in Craigavon, Northern Ireland. Almac Diagnostic Services delivers diverse biomarker discovery, development, and commercialization solutions to global biopharmaceutical partners.